文献速递消化系统肿瘤

整合组织活检与液体活检全面基因组分析预测转移性结直肠癌抗EGFR治疗疗效:CAPRI-2 GOIM研究结果

Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.
PubMed 文献 · Eur J Cancer · 2025-07-12

CAPRI-2 GOIM研究纳入156例RAS/BRAFV600E野生型转移性结直肠癌患者,基线时用FoundationOne CDx平台分析组织活检与液体活检的全面基因组分析,评估其预测FOLFIRI联合西妥昔单抗疗效的作用。组织与液体活检均阴性超选择的患者ORR更高(79.6% vs 44.2%,P<0.001),mPFS更长(12.4个月 vs 7.4个月,P<0.001)。高循环肿瘤DNA分数时液体活检可预测抗EGFR疗效,分数<10%时组织活检可提供额外致病变异信息。

要点

  • 组织与液体活检均阴性超选择者ORR 79.6% vs 44.2%,mPFS 12.4 vs 7.4个月,均P<0.001
  • 仅组织活检检出突变的患者ctDNA分数显著低于一致组(1.7% vs 23.0%,P=0.01)
  • ctDNA分数阈值≥10%时,20例组织活检致病变异中19例液体活检也检出

核心结论

  • 在高肿瘤分数时液体活检全面基因组分析可预测抗EGFR治疗疗效,肿瘤分数<10%时组织活检可提供可能影响疗效的额外致病变异信息。

研究设计与样本

  • CAPRI-2 GOIM研究为非随机2期研究,评估生物标志物驱动的抗EGFR治疗在三线治疗中用于RAS/BRAFV600E野生型转移性结直肠癌患者。
  • 基线时采用FoundationOne CDx平台分析组织活检与液体活检的全面基因组分析。
  • 共156例患者可评估肿瘤缓解且具有配对的组织与血浆全面基因组分析。

主要发现

  • 组织与液体活检全面基因组分析均阴性超选择的患者ORR为79.6% vs 突变病例44.2%(P<0.001),mPFS为12.4个月 vs 7.4个月(P<0.001)。
  • 仅组织活检检出突变8例,仅液体活检检出突变12例。
  • 与不一致病例(n=20)相比,一致病例(n=23)ORR有降低趋势(39.1% vs 50.0%,P=0.5),mPFS更短(3.94 vs 11.50个月,P=0.02)。
  • 仅组织活检检出变异的患者ctDNA肿瘤分数显著低于一致病例(1.7% vs 23.0%,P=0.01)。
  • 采用ctDNA肿瘤分数阈值≥10%时,20例组织活检检出的致病变异中19例液体活检也检出;仅液体活检检出的8例mPFS为8.24个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We investigated the role of integrating tissue biopsy (TBx)- and liquid biopsy (LBx)-comprehensive genomic profiling (CGP) to predict the activity of FOLFIRI plus cetuximab. METHODS: The CAPRI-2 GOIM study is a non-randomized phase 2 study evaluating a biomarker-driven anti-EGFR treatment in three lines of therapy in patients with RAS/BRAFV600E wild type metastatic colorectal cancer. At baseline, TBx and LBx were analyzed using the FoundationOne CDx platform. Analysis of overall response rate (ORR) and median progression free survival (mPFS) according to molecular profiles were performed. RESULTS: Overall, 156 patients were evaluable for tumor response and had matched tissue and plasma-based CGP. Negatively hyper-selected patients by both TBx- and LBx-CGP showed higher ORR (79.6 % versus 44.2 %, P < 0.001) and mPFS compared to mutated cases (12.4 months versus 7.4 months, P < 0.001). Eight and 12 cases harbored mutations detected by TBx and LBx-CGP only, respectively. Compared to discordant cases (n = 20), concordant cases (n = 23) showed a trend for lower ORR (39.1 % versus 50.0 %, P = 0.5) and shorter mPFS (3.94 versus 11.50 months, P = 0.02). Patients with alterations detected only by TBx-CGP had significantly lower circulating tumor DNA (ctDNA) tumor fraction (TF) compared to concordant cases (1.7 % versus 23.0 %; P = 0.01). Using a ctDNA TF threshold ≥ 10 % nearly all (19 of 20) TBx detected pathogenic variants (PV) were also identified by LBx-CGP. In eight cases detected by LBx only, mPFS was 8.24 months. CONCLUSION: In cases with high TF LBx-CGP predicts efficacy of anti-EGFR therapy, while for TF< 10 % TBx-CGP provides additional data on PVs that could affect treatment efficacy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ciardiello D, Boscolo Bielo L, Napolitano S, et al. Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study. Eur J Cancer. 2025. PMID: 40669385. doi:10.1016/j.ejca.2025.115642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。